Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study

Autor: Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Nicolas Schleif, Ursula Cirrincione, Axel Hinke, Gabriele Feisel-Schwickardi

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)

Abstract Background The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clinical studies. Methods

Externí odkaz: https://doaj.org/article/e43f4c5e114d4a3d89db10e70b8f4cd8

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Autor: Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean, Alexander Hein, Alain G Zeimet, Lars C Hanker, Thierry Petit, Frederik Marmé, Ahmed El-Balat, Rosalind Glasspool, Nikolaus de Gregorio, Sven Mahner, Tarek M Meniawy, Tjoung-Won Park-Simon, Marie-Ange Mouret-Reynier, Cristina Costan, Werner Meier, Alexander Reinthaller, Jeffrey C Goh, Tifenn L'Haridon, Sally Baron Hay, Stefan Kommoss, Andreas du Bois, Jean-Emmanuel Kurtz, Sven Ackermann, Christoph Anthuber, Mustafa Aydogdu, Angelika Baldauf, Wolfgang Bauer, Dirk Behringer, Antje Belau, Alexandra Bender, Cosima Brucker, Alexander Burges, Trygve Daabach, Dominik Denschlag, Mustafa Deryal, Steffen Dörfel, Juliane Ebert, Tanja Fehm, Susanne Maria Feidicker, Gabriele Feisel-Schwickardi, Ricardo Felberbaum, Matthias Frank, Gerhard Gebauer, Bernd Gerber, Axel Gerhardt, Andrea Grafe, Martin Griesshammer, Eva-Maria Grischke, Isolde Gröll, Martina Gropp-Meier, Dietrich Hager, Volker Hanf, Carla Verena Hannig, Peer Hantschmann, Tanja Hauzenberger, Uwe Herwig, Martin Heubner, Carsten Hielscher, Felix Hilpert, Thomas Hitschold, Manfred Hofmann, Christian Jackisch, Wolfgang Janni, Ludwig Kiesel, Yon-Dschun Ko, Hans-Joachim Koch, Petra Krabisch, Peter Krieger, Thomas Kubin, Thorsten Kühn, Björn Lampe, Peter Ledwon, Sabine Lemster, Benno Lex, Clemens Liebrich, Ralf Lorenz, Hans-Joachim Lück, Peter Mallmann, Wolfgang Meinerz, Götz Menke, Volker Möbus, Thomas Müller, Volker Müller, Tanja Neunhöffer, Angelika Ober, Gülten Oskay-Özcelik, Horst Ostertag, Martin Pölcher, Beate Rautenberg, Daniel Rein, Wilhelm Reiter, Andreas Rempen, Ingo Runnebaum, Marcus Schmidt, Sabine Schnohr, Heinz Scholz, Willibald Schröder, Eike Simon, Antje Sperfeld, Annette Steckkönig, Hans-Georg Strauß, Ronaldo Stuth, Jürgen Terhaag, Falk Thiel, Marc Thill, Oliver Tomé, Christoph Uleer, Susanne Vogel, Hermann Voß, Michael Weigel, Ulrich Winkler, Arthur Wischnik, Tobias Zeiser, Andreas Zorr, Ros Glasspool, Emma Hudson, Rachel Jones, Judith Lafleur, Christian Marth, Edgar Petru, Yoland Antill, Mary Azer, Sally Baron-Hay, Philip Beale, Stephen Begbie, Allison Black, Karen Briscoe, Andrew Dean, Jeffrey Goh, Sandra Harvey, Chee Lee, Marco Matos, Tarek Meniawy, Inger Olesen, Catherine Shannon, Paul Vasey, Sophie Abadie-Lacourtoisie, Olivier Arsene, Sophie Barthier, Célia Becuwe-Roemer, Dominique Berton-Rigaud, Maria Cappiello-Bataller, Stéphanie Catala, Francesco Del Piano, Gaël Deplanque, Raymond Despax, Nadine Dohollou, Claire Garnier-Tixidré, Julien Grenier, Emmanuel Guardiola, Anne-Claire Hardy-Bessard, Claudia Lefeuvre-Plesse, Marianne Leheurteur, Anne Lesoin, Charles-Briac Levache, Raffaele Longo, Alain Lortholary, Jérôme Meunier, Nadia Raban, Olivier Romano, Jean-Michel Vannetzel, Alain Zannetti

Publikováno v: Lancet Oncology
Lancet Oncology, 2020, 21 (5), pp.699-709. ⟨10.1016/S1470-2045(20)30142-X⟩
The Lancet Oncology
The Lancet Oncology, 2020, 21 (5), pp.699-709. ⟨10.1016/S1470-2045(20)30142-X⟩

Background:\ud State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin–paclitaxel or carboplatin–gemcitabine) or the mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6dcdfeb9666bdc098f5e231578e0974
https://hal.science/hal-02887894

Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

Autor: Thomas Göhler, Carsten Hielscher, A Wischnik, Peter Dall, Axel Hinke, Stella Keitel, Gabriele Feisel-Schwickardi, Andreas Ammon, Daniela Rezek, Ursula Cirrincione, Jochen Eggert, Thorsten Koch, Nidal Gazawi, Johannes Selbach

Publikováno v: The oncologist. 22(2)

Purpose Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17499fe072eb9d590d5ecfa0af958ae8
https://pubmed.ncbi.nlm.nih.gov/28174294

Quality of patient-reported outcome for long-term survival of early breast cancer trials

Autor: Wolfgang Janni, Tanja Neunhoeffer, Gabriele Feisel, Michael Wittenberg, Hans Georg Lenhard, Valentina Nekljudova, Jan Steffen, Iris Schrader, Serban-Dan Costa, Uwe E. Kullmer, Sibylle Loibl, Gunter von Minckwitz, Volkmar Müller, Marc Thill

Publikováno v: Journal of Clinical Oncology. 34:e18121-e18121

e18121Background: Follow up (FU) of long term survival in early breast cancer (BC) trials is highly important as treatment effects might change over time and have to be related to late or chronic t...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::90568a0076d5bed8a6d40232de62a0bc
https://doi.org/10.1200/jco.2016.34.15_suppl.e18121

Genomic alterations in paired pretreatment (pre) and progression (prog) tumor samples from ovarian cancer patients (pts) treated with pazopanib (pazo) or placebo (plb)

Autor: Sandrina Lambrechts, Anthony D'Amelio, Jae Weon Kim, Philipp Harter, Andres Poveda, Yuan Liu, Ulrich Canzler, Tjoung-Won Park-Simon, Gabriele Feisel, Nuria Lainez, Robert C. Gagnon, Alexander Burges, Annette Jahn, Ionel Mitrica, Rafael ÃÂlvarez Gallego, Sang Yoon Park, Kosei Hasegawa, Catherine Barrett, Florian Heitz, Mansoor Raza Mirza

Publikováno v: Journal of Clinical Oncology. 32:5501-5501

5501 Background: BRCA mutational status, in combination with the accumulation of somatic mutations, has been associated with ovarian cancer prog and response to chemotherapy. AGO-OVAR16/VEG110655 i...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30d350901e8105d912dbc757f27e0ce0
https://doi.org/10.1200/jco.2014.32.15_suppl.5501